Moreover, several studies shed light on RAG1 patients bearing the same mutation can have different clinical manifestations and outcomes [6,42] and RAG1 mutations driving partial RAG1 deficiency are associated with immune dysregulation [43,44] that could affect GT efficacy. This evidence concerns the gene RAG1 and hyperinsulinemic hypoglycemia, familial, 4.